Technology ID
E-079-2011-0

Fast Acting Molecular Probes for Real-Time In Vivo Study of Disease and Therapeutics

Linked ID
TAB-2453
Inventors
Lei Zhu (NIBIB)
Seulki Lee (NIBIB)
Xiaoyuan Chen (NIBIB)
Lead Inventors
Xiaoyuan Chen (NIBIB)
Co-Inventors
Lei Zhu (NIBIB)
Seulki Lee (NIBIB)
Development Status
  • Early-stage
  • Pre-clinical
  • In vivo data available (animal)
Applications
Research Materials
Diagnostics
ICs
NIBIB
Commercial Applications
  • Diagnostics
  • In vivo therapeutic monitoring
This technology is for fast acting molecular probes made from a fluorescent quencher molecule, a fluorophore, an enzyme cleavable oligopeptide (for example targeted by protease) and FDA-approved polyethylene glycol (PEG) as well as associated methods to identify cell activity with these probes. Proteases regulate many cell processes such as inflammation as well as pathological processes in cancer and cardiovascular disease. High protease activity is associated with metastatic cancers. Proteases are also active in apoptosis, and tissue remodeling in cardiovascular disease. Although highly useful in vitro, conventional probes are unstable, nonspecific or slow activating in vivo. This new probe is faster than standard probes (30 min vs. 24 hrs) and has enhanced target-to background ratios. It enables quick screening of animals in an array of applications related to protease-associated diseases and other diseases. It may detect specific biological targets and monitor in vivo therapeutic efficacy in real time. Most drug candidates identified by in vitro screening fail in vivo. Failures are costly. Identifying in vivo drug efficacy sooner would reduce waste and increase successful drug development.
Competitive Advantages
  • Faster than standard probes
  • Enhanced target-to-background ratios
  • Allows in vivo therapeutic efficacy study in real time

Request More Info

Licensing Contact